ACTRN12613001121752招募中2 期
Effect of Cabergoline Vs placebo on HbA1C, HOMA-IR, HOMA-Beta, FPG, anthropometric parameters in patient with Impaired fasting glucose/Impaired glucose tolerance.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 20 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Fasting Plasma Glucose (FPG): 100-110 mg/dL or/and 2 hour Plasma Glucose after Oral Glucose Tolerance Test (2hPG): 140-199 mg/dL.
排除标准
- •1) severe hepatic failure (Child-Pugh scores of 10 or higher)
- •2) history of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders; increased risk of pleural effusion/pulmonary fibrosis
- •3) hypersensitivity to ergot derivatives
- •4) uncontrolled hypertension
- •5) Diabetes
- •6) Pregnant Women
- •7) Lactating Women
- •8) Major psychiatric disorders
- •9) Recieving Medication effect prolactin secretion
- •10) Bulimia or/and anorexia nervosa
研究者
相似试验
招募中
2 期
Cabergolin effect on IVF for endometriosisIRCT20091012002576N35Tehran University of Medical Sciences200
已完成
2 期
Effect of Cabergoline on biochemical and anthropometric parameters of patients with prediabetes.Impaired Glucose Tolerance/Impaired Fasting Glucos.Impaired glucose tolerance (oral)R73.02IRCT20170608034390N6Shahid Beheshti University of Medical Sciences98
招募中
3 期
The effect of Cabergoline on blood glucose control in type 2 diabetic patientsIRCT20100314003565N9Tabriz University of Medical Sciences50
Unknown
3 期
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM PatientsDiabetesNCT03313661Sherief Abd-Elsalam60
已完成
3 期
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminType 2 Diabetes MellitusNCT02926950Lexicon Pharmaceuticals518